Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of biweekly doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple-negative (TN), HER2-neu-positive (HER2+), or locally advanced breast cancer (LABC): Preliminary results of a prospective, phase II, nonrandomized study

Autor: A. Klitsa, C. Georgakopoulos, N. Desses, P. Thomou, G. Xepapadakis, M. Tsantekidou, M. Vassilaki, A. Sioulas
Rok vydání: 2010
Předmět:
Zdroj: Journal of Clinical Oncology. 28:e11006-e11006
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2010.28.15_suppl.e11006
Popis: e11006 Background: PLcs are active in TN locally advanced and metastatic breast cancer. This study aims to assess efficacy and safety resulting from the addition of cisplatin or carboplatin to a st...
Databáze: OpenAIRE